ArticleJournal of virology1994
Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.
Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 115 citations in OpenAlex.
- Endogenous Avian Leukosis Virus in Combination with Serotype 2 Marek's Disease Virus Significantly Boosted the Incidence of Lymphoid Leukosis-Like Bursal Lymphomas in Susceptible Chickens.Journal of virology · 2019Article
- The Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell.Human gene therapy methods · 2013Article
- Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010Review
- Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule.Virology journal · 2010Article
- A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.The journal of gene medicine · 2009Article
- Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins.The journal of gene medicine · 2009Article
- Targeting lentiviral vectors to specific cell types in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.PLoS biology · 2004Article
- Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.Gene therapy · 2004Article
- Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.Human gene therapy · 2003Article
- Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope.Journal of virology · 2002Article
- Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein.Journal of virology · 2001Article
- Antibody-directed targeting of retroviral vectors via cell surface antigens.Journal of virology · 2001Article
- A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.Human gene therapy · 2001Article
- A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.Journal of virology · 2000Article
- Viral vectors for gene transfer: a review of their use in the treatment of human diseases.Drugs · 2000Review
- Retroviral membrane display of apoptotic effector molecules.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On the basis of theoretical structural and comparative studies of various avian leukosis virus SU (surface) envelope proteins, we have identified four small regions (I, II, III, and IV) in their receptor-binding domains that could potentially be involved in binding to receptors. From the envelope gene of an avian leukosis virus of subgroup A, we have constructed a set of SU mutants in which these regions were replaced by the coding sequence of FLA16, a 16-amino-acid RGD-containing peptide known to be the target for several cellular integrin receptors. Helper-free retroviral particles carrying a neo-lacZ retroviral vector were produced with the mutant envelopes. SU mutants in which regions III and IV were substituted yielded normal levels of envelope precursors but were not detectably processed or incorporated in viral particles. In contrast, substitutions in regions I and II did not affect the processing and the viral incorporation of SU mutants. When FLA16 was inserted in region II, it could be detected with antibodies against FLA16 synthetic peptide, but only when viral particles were deglycosylated. Viral particles with envelopes mutated in region I or II were able to infect avian cells through the subgroup A receptor at levels similar to those of the wild type. When viruses with envelopes containing FLA16 peptide in region II were applied to plastic dishes, they were found to promote binding of mammalian cells resistant to infection by subgroup A avian leukosis viruses but expressing the integrins recognized by FLA16. Deglycosylated helper-free viruses obtained by mild treatment with N-glycosidase F have been used to infect these mammalian cells, and infections have been monitored by neomycin selection. No neomycin-resistant clones could be obtained after infection by viruses with wild-type envelopes. Conversely, colonies were obtained after infection by viruses with envelopes bearing FLA16 in region II, and the genome of the retroviral vector was found correctly integrated in cell DNA of these colonies. By using a blocking peptide containing the minimal adhesive RGD sequence contained in FLA16, we have shown that preincubation of target cells could specifically inhibit infection by viruses with FLA16.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.